REFERENCES
2. Paciello F, Pisani A, Rinaudo M, et al. Noise-induced auditory damage affects hippocampus causing memory deficits in a model of early age-related hearing loss. Neurobiol Dis 2023;178:106024.
3. Lin BM, Wang M, Stankovic KM, et al. Cigarette smoking, smoking cessation, and risk of hearing loss in women. Am J Med 2020;133:1180-6.
4. Kros CJ, Steyger PS. Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies. Cold Spring Harb Perspect Med 2019;9:a033548.
5. Shen Y, Ye B, Chen P, et al. Cognitive decline, dementia, Alzheimer’s disease and presbycusis: examination of the possible molecular mechanism. Front Neurosci 2018;12:394.
6. Jafari Z, Kolb BE, Mohajerani MH. Age-related hearing loss and tinnitus, dementia risk, and auditory amplification outcomes. Ageing Res Rev 2019;56:100963.
7. Chern A, Golub JS. Age-related hearing loss and dementia. Alzheimer Dis Assoc Disord 2019;33:285-90.
8. He P, Wen X, Hu X, et al. Hearing aid acquisition in chinese older adults with hearing loss. Am J Public Health 2018;108:241-7.
12. Sheladia S, Reddy PH. Age-related chronic diseases and Alzheimer’s disease in texas: a hispanic focused study. J Alzheimers Dis Rep 2021;5:121-33.
13. Gowda P, Reddy PH, Kumar S. Deregulated mitochondrial microRNAs in Alzheimer’s disease: focus on synapse and mitochondria. Ageing Res Rev 2022;73:101529.
16. Power R, Prado-Cabrero A, Mulcahy R, Howard A, Nolan JM. The role of nutrition for the aging population: implications for cognition and Alzheimer’s disease. Annu Rev Food Sci Technol 2019;10:619-39.
17. Kay DW, Roth M, Beamish P. Old age mental disorders in newcastle upon tyen. II. A study of possible social and medical causes. Br J Psychiatry 1964;110:668-82.
18. Kiely KM, Gopinath B, Mitchell P, Luszcz M, Anstey KJ. Cognitive, health, and sociodemographic predictors of longitudinal decline in hearing acuity among older adults. J Gerontol A Biol Sci Med Sci 2012;67:997-1003.
19. Rutherford BR, Brewster K, Golub JS, Kim AH, Roose SP. Sensation and psychiatry: linking age-related hearing loss to late-life depression and cognitive decline. Am J Psychiatry 2018;175:215-24.
20. Stickel AM, Mendoza A, Tarraf W, et al. Hearing loss and associated 7-year cognitive outcomes among hispanic and latino adults. JAMA Otolaryngol Head Neck Surg 2024;150:385-92.
21. Cantuaria ML, Pedersen ER, Waldorff FB, et al. Hearing loss, hearing aid use, and risk of dementia in older adults. JAMA Otolaryngol Head Neck Surg 2024;150:157-64.
22. Lin FR, Pike JR, Albert MS, et al; ACHIEVE Collaborative Research Group. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet 2023;402:786-97.
23. Kwok SS, Nguyen XT, Wu DD, Mudar RA, Llano DA. Pure tone audiometry and hearing loss in Alzheimer’s disease: a meta-analysis. Front Psychol 2021;12:788045.
24. Johnson JCS, Marshall CR, Weil RS, Bamiou DE, Hardy CJD, Warren JD. Hearing and dementia: from ears to brain. Brain 2021;144:391-401.
25. Merchant SN, Nadol Jr JB. Schuknecht’s pathology of the ear. 3rd ed. Shelton, CT: People’s Medical House-USA; 2010. Available from: https://books.google.com/books?id=cUEKaR0x-XUC&printsec=frontcover&hl=zh-CN#v=onepage&q&f=false. [Last accessed on 27 Nov 2024].
26. Schuknecht HF, Gacek MR. Cochlear pathology in presbycusis. Ann Otol Rhinol Laryngol 1993;102:1-16.
27. Suga F, Lindsay JR. Histopathological observations of presbycusis. Ann Otol Rhinol Laryngol 1976;85:169-84.
28. Ohlemiller KK. Age-related hearing loss: the status of Schuknecht’s typology. Curr Opin Otolaryngol Head Neck Surg 2004;12:439-43.
29. Bhattacharyya TK, Dayal VS. Influence of age on hair cell loss in the rabbit cochlea. Hear Res 1989;40:179-83.
30. Wright A, Davis A, Bredberg G, Ulehlova L, Spencer H. Hair cell distributions in the normal human cochlea. Acta Otolaryngol Suppl 1987;444:1-48.
31. Makary CA, Shin J, Kujawa SG, Liberman MC, Merchant SN. Age-related primary cochlear neuronal degeneration in human temporal bones. J Assoc Res Otolaryngol 2011;12:711-7.
32. Pauler M, Schuknecht HF, Thornton AR. Correlative studies of cochlear neuronal loss with speech discrimination and pure-tone thresholds. Arch Otorhinolaryngol 1986;243:200-6.
33. Pauler M, Schuknecht HF, White JA. Atrophy of the stria vascularis as a cause of sensorineural hearing loss. Laryngoscope 1988;98:754-9.
34. Schuknecht HF. Further observations on the pathology of presbycusis. Arch Otolaryngol 1964;80:369-82.
35. Nelson EG, Hinojosa R. Presbycusis: a human temporal bone study of individuals with downward sloping audiometric patterns of hearing loss and review of the literature. Laryngoscope 2006;116:1-12.
36. Yamasoba T, Lin FR, Someya S, Kashio A, Sakamoto T, Kondo K. Current concepts in age-related hearing loss: epidemiology and mechanistic pathways. Hear Res 2013;303:30-8.
38. Böttger EC, Schacht J. The mitochondrion: a perpetrator of acquired hearing loss. Hear Res 2013;303:12-9.
39. Someya S, Prolla TA. Mitochondrial oxidative damage and apoptosis in age-related hearing loss. Mech Ageing Dev 2010;131:480-6.
40. Darrat I, Ahmad N, Seidman K, Seidman MD. Auditory research involving antioxidants. Curr Opin Otolaryngol Head Neck Surg 2007;15:358-63.
41. Seidman MD. Effects of dietary restriction and antioxidants on presbyacusis. Laryngoscope 2000;110:727-38.
42. Yamasoba T, Someya S, Yamada C, Weindruch R, Prolla TA, Tanokura M. Role of mitochondrial dysfunction and mitochondrial DNA mutations in age-related hearing loss. Hear Res 2007;226:185-93.
43. Jiang H, Talaska AE, Schacht J, Sha SH. Oxidative imbalance in the aging inner ear. Neurobiol Aging 2007;28:1605-12.
44. Coling D, Chen S, Chi LH, Jamesdaniel S, Henderson D. Age-related changes in antioxidant enzymes related to hydrogen peroxide metabolism in rat inner ear. Neurosci Lett 2009;464:22-5.
45. Mikhed Y, Daiber A, Steven S. Mitochondrial oxidative stress, mitochondrial DNA damage and their role in age-related vascular dysfunction. Int J Mol Sci 2015;16:15918-53.
47. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J Obes Relat Metab Disord 2003;27 Suppl 3:S29-34.
48. Adams JC. Clinical implications of inflammatory cytokines in the cochlea: a technical note. Otol Neurotol 2002;23:316-22.
49. Wells HRR, Newman TA, Williams FMK. Genetics of age-related hearing loss. J Neurosci Res 2020;98:1698-704.
50. Van Laer L, Huyghe JR, Hannula S, et al. A genome-wide association study for age-related hearing impairment in the Saami. Eur J Hum Genet 2010;18:685-93.
51. Arsenijevic D, Onuma H, Pecqueur C, et al. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 2000;26:435-9.
52. Unal M, Tamer L, Doğruer ZN, Yildirim H, Vayisoğlu Y, Camdeviren H. N-acetyltransferase 2 gene polymorphism and presbycusis. Laryngoscope 2005;115:2238-41.
53. Boucher S, Tai FWJ, Delmaghani S, et al. Ultrarare heterozygous pathogenic variants of genes causing dominant forms of early-onset deafness underlie severe presbycusis. Proc Natl Acad Sci U S A 2020;117:31278-89.
54. Girotto G, Pirastu N, Sorice R, et al. Hearing function and thresholds: a genome-wide association study in European isolated populations identifies new loci and pathways. J Med Genet 2011;48:369-74.
55. Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clin Biochem 2019;72:87-9.
56. Liu T, Woo JA, Yan Y, LePochat P, Bukhari MZ, Kang DE. Dual role of cofilin in APP trafficking and amyloid-β clearance. FASEB J 2019;33:14234-47.
57. Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med 2018;284:643-63.
58. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s disease. Alzheimers Res Ther 2019;11:34.
59. Blennow K. A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood. Neurol Ther 2017;6:15-24.
60. Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, et al. Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer’s disease models and human brains. Acta Neuropathol 2021;141:39-65.
61. Nabers A, Perna L, Lange J, et al. Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol Med 2018;10:e8763.
62. John A, Reddy PH. Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev 2021;65:101208.
63. Zhu M, Wang X, Sun L, Schultzberg M, Hjorth E. Can inflammation be resolved in Alzheimer’s disease? Ther Adv Neurol Disord 2018;11:1756286418791107.
64. Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P, Grubeck-Loebenstein B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis 2000;7:682-9.
65. Kerr JS, Adriaanse BA, Greig NH, et al. Mitophagy and Alzheimer’s disease: cellular and molecular mechanisms. Trends Neurosci 2017;40:151-66.
66. Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis 2018;62:1403-16.
67. Liang T, Hang W, Chen J, et al. ApoE4 (Δ272-299) induces mitochondrial-associated membrane formation and mitochondrial impairment by enhancing GRP75-modulated mitochondrial calcium overload in neuron. Cell Biosci 2021;11:50.
69. Song M, Fan X. Systemic metabolism and mitochondria in the mechanism of Alzheimer’s disease: finding potential therapeutic targets. Int J Mol Sci 2023;24:8398.
70. Shoshan-Barmatz V, Nahon-Crystal E, Shteinfer-Kuzmine A, Gupta R. VDAC1, mitochondrial dysfunction, and Alzheimer’s disease. Pharmacol Res 2018;131:87-101.
71. Olesen MA, Villavicencio-Tejo F, Quintanilla RA. The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders. Transl Neurodegener 2022;11:36.
72. James D, Kang S, Park S. Injection of β-amyloid into the hippocampus induces metabolic disturbances and involuntary weight loss which may be early indicators of Alzheimer’s disease. Aging Clin Exp Res 2014;26:93-8.
73. Liguori C, Chiaravalloti A, Sancesario G, et al. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2016;43:2040-9.
74. Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017;13:629-46.
75. Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. J Alzheimers Dis 2017;57:1105-21.
77. Guan S, Zhao L, Peng R. Mitochondrial respiratory chain supercomplexes: from structure to function. Int J Mol Sci 2022;23:13880.
78. Liu Y, Huang Y, Xu C, et al. Mitochondrial dysfunction and therapeutic perspectives in cardiovascular diseases. Int J Mol Sci 2022;23:16053.
79. Brand MD. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. Free Radic Biol Med 2016;100:14-31.
80. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. Biochim Biophys Acta 2010;1802:2-10.
81. Mi Y, Qi G, Brinton RD, Yin F. Mitochondria-targeted therapeutics for Alzheimer’s disease: the good, the bad, the potential. Antioxid Redox Signal 2021;34:611-30.
82. Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012;36:401-14.
83. Zhao M, Wang Y, Li L, et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics 2021;11:1845-63.
84. O’Hara R, Tedone E, Ludlow A, et al. Quantitative mitochondrial DNA copy number determination using droplet digital PCR with single-cell resolution. Genome Res 2019;29:1878-88.
85. Nikolac Perkovic M, Videtic Paska A, Konjevod M, et al. Epigenetics of Alzheimer’s disease. Biomolecules 2021;11:195.
86. Li Y, Xia X, Wang Y, Zheng JC. Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer’s disease. J Neuroinflammation 2022;19:248.
87. Podlesniy P, Figueiro-Silva J, Llado A, et al. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Ann Neurol 2013;74:655-68.
88. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014;128:755-66.
89. Zhu B, Liu Y, Hwang S, et al. Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. Mol Neurodegener 2022;17:58.
92. Shin MK, Vázquez-Rosa E, Koh Y, et al. Reducing acetylated tau is neuroprotective in brain injury. Cell 2021;184:2715-32.e23.
93. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9:106-18.
94. Huang YA, Zhou B, Wernig M, Südhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion. Cell 2017;168:427-41.e21.
95. Robert J, Button EB, Yuen B, et al. Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. Elife 2017;6:e29595.
96. Hashimoto T, Serrano-Pozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci 2012;32:15181-92.
97. Bonham LW, Desikan RS, Yokoyama JS; Alzheimer’s disease neuroimaging initiative. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer’s disease. Acta Neuropathol Commun 2016;4:65.
98. Dorey E, Bamji-Mirza M, Najem D, et al. Apolipoprotein E isoforms differentially regulate Alzheimer’s disease and amyloid-β-induced inflammatory response in vivo and in vitro. J Alzheimers Dis 2017;57:1265-79.
99. den Haan J, Morrema THJ, Verbraak FD, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas. Acta Neuropathol Commun 2018;6:147.
100. Doustar J, Torbati T, Black KL, Koronyo Y, Koronyo-Hamaoui M. Optical coherence tomography in Alzheimer’s disease and other neurodegenerative diseases. Front Neurol 2017;8:701.
101. Shi H, Koronyo Y, Rentsendorj A, et al. Identification of early pericyte loss and vascular amyloidosis in Alzheimer’s disease retina. Acta Neuropathol 2020;139:813-36.
102. Eisele YS, Duyckaerts C. Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 2016;131:5-25.
103. Gaire BP, Koronyo Y, Fuchs DT, et al. Alzheimer’s disease pathophysiology in the Retina. Prog Retin Eye Res 2024;101:101273.
104. Zheng M, Yan J, Hao W, et al. Worsening hearing was associated with higher β-amyloid and tau burden in age-related hearing loss. Sci Rep 2022;12:10493.
105. Omata Y, Tharasegaran S, Lim YM, et al. Expression of amyloid-β in mouse cochlear hair cells causes an early-onset auditory defect in high-frequency sound perception. Aging 2016;8:427-39.
106. Mathiesen BK, Miyakoshi LM, Cederroth CR, et al. Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice. Sci Transl Med 2023;15:eabq3916.
107. Fukuda M, Okanishi H, Ino D, et al. Disturbance in the protein landscape of cochlear perilymph in an Alzheimer’s disease mouse model. PLoS One 2024;19:e0303375.
108. Saito T, Matsuba Y, Mihira N, et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci 2014;17:661-3.
109. Toescu EC, Verkhratsky A, Landfield PW. Ca2+ regulation and gene expression in normal brain aging. Trends Neurosci 2004;27:614-20.
110. Ouda L, Burianova J, Syka J. Age-related changes in calbindin and calretinin immunoreactivity in the central auditory system of the rat. Exp Gerontol 2012;47:497-506.
111. Banay-Schwartz M, Lajtha A, Palkovits M. Changes with aging in the levels of amino acids in rat CNS structural elements. II. Taurine and small neutral amino acids. Neurochem Res 1989;14:563-70.
112. Courchesne E, Chisum HJ, Townsend J, et al. Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology 2000;216:672-82.
113. Lemaitre H, Goldman AL, Sambataro F, et al. Normal age-related brain morphometric changes: nonuniformity across cortical thickness, surface area and gray matter volume? Neurobiol Aging 2012;33:617.e1-9.
114. Guo X, Skoog I, Idrizbegovic E, Pantoni L, Simoni M, Rosenhall U. Hearing loss and cortical atrophy in a population-based study on non-demented women. Age Ageing 2008;37:333-6.
115. Kaiser LG, Schuff N, Cashdollar N, Weiner MW. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. Neurobiol Aging 2005;26:665-72.
116. Schubert F, Gallinat J, Seifert F, Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 2004;21:1762-71.
117. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:119-28.
118. Li K, Qu H, Ma M, et al. Correlation between brain structure atrophy and plasma amyloid-β and phosphorylated tau in patients with Alzheimer’s disease and amnestic mild cognitive impairment explored by surface-based morphometry. Front Aging Neurosci 2022;14:816043.
119. Reddy PH, Yin X, Manczak M, et al. Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease. Hum Mol Genet 2018;27:2502-16.
120. Na D, Zhang J, Beaulac HJ, et al. Increased central auditory gain in 5xFAD Alzheimer’s disease mice as an early biomarker candidate for Alzheimer’s disease diagnosis. Front Neurosci 2023;17:1106570.
121. Hidisoglu E, Yargicoglu P. Auditory evoked potentials might have the potential to serve as early indicators related to amyloid beta peptide toxicity. Adv Med Sci 2020;65:223-32.
122. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800.
123. Zhao H, Wang Y, Cui L, et al. Sensorineural hearing loss and cognitive impairment: three hypotheses. Front Aging Neurosci 2024;16:1368232.
124. Shukla A, Harper M, Pedersen E, et al. Hearing loss, loneliness, and social isolation: a systematic review. Otolaryngol Head Neck Surg 2020;162:622-33.
125. Qian ZJ, Chang PD, Moonis G, Lalwani AK. A novel method of quantifying brain atrophy associated with age-related hearing loss. Neuroimage Clin 2017;16:205-9.
126. Albers MW, Gilmore GC, Kaye J, et al. At the interface of sensory and motor dysfunctions and Alzheimer’s disease. Alzheimers Dement 2015;11:70-98.
127. Lin FR, Metter EJ, O’Brien RJ, Resnick SM, Zonderman AB, Ferrucci L. Hearing loss and incident dementia. Arch Neurol 2011;68:214-20.
128. Luan Y, Wang C, Jiao Y, Tang T, Zhang J, Teng GJ. Prefrontal-temporal pathway mediates the cross-modal and cognitive reorganization in sensorineural hearing loss with or without tinnitus: a multimodal MRI study. Front Neurosci 2019;13:222.
129. Dai L, Best V, Shinn-Cunningham BG. Sensorineural hearing loss degrades behavioral and physiological measures of human spatial selective auditory attention. Proc Natl Acad Sci U S A 2018;115:E3286-95.
130. Martorell AJ, Paulson AL, Suk HJ, et al. Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell 2019;177:256-71.e22.
131. Harrington MO, Cairney SA. Sounding it out: auditory stimulation and overnight memory processing. Curr Sleep Med Rep 2021;7:112-9.
132. Rocchi F, Oya H, Balezeau F, et al. Common fronto-temporal effective connectivity in humans and monkeys. Neuron 2021;109:852-68.e8.
133. Vassena E, Deraeve J, Alexander WH. Surprise, value and control in anterior cingulate cortex during speeded decision-making. Nat Hum Behav 2020;4:412-22.
134. Zemaitis K, Kaliyappan K, Frerichs V, Friedman A, Krishnan Muthaiah VP. Mass spectrometry imaging of blast overpressure induced modulation of GABA/glutamate levels in the central auditory neuraxis of Chinchilla. Exp Mol Pathol 2021;119:104605.
